49 results about "Parental cell" patented technology

The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods. The subject methods, systems, and kits find use in a variety of different industrial, medical and research applications.

Provided herein are a hybridoma cell line producing monoclonal antibody against foot-and-mouth disease virus (FMDV), the monoclonal antibody therefrom, reagent and kit for ELISA, and immunoassay method. The hybridoma cell line is produced by cell fusion of a parental cell and a myeloma cell line and has the same characteristics as the cell line whose strain designation is CmA40 and deposition number is ATCC (To be Provided). The parental cell is a splenocyte isolated from the spleen of a mouse immunized by an antigen derived from a 3ABC non-structural protein (NSP) of FMDV. The antigen used here is expressed by a prokaryotic cell. The monoclonal antibody produced by the hybridoma cell line can specifically recognize a 3ABC polypeptide and does not cross-react with an antiserum of swine vesicular disease virus.

The invention relates to a multidrug resistant cell strain for oophoroma, which is characterized in that a human oophoroma SKOV3 cell strain is selected as a parental cell; the action concentration of chemotherapeutics of etoposide (VP16) is gradually increased from 0.1 mu g/ml to 3 mu g/ml; and drug resistant SKOV3/VP16 cell strain is established. The SKOV3/VP16 cell can stably grow, transfer and reanimate in 3 mu g/ml VP16, makes the VP16 generate drug resistant index (RI) of 21.548, and performs intersect drug on MTX, DOX, DDP, VCR, 5-Fu and MMC except the VP16. The invention aims to provide a drug resistant tumor cell model for relative study on the tumor.

The invention provides a hybridoma cell line and a monoclonal antibody thereof, an immune detection reagent containing the monoclonal antibody and a kit thereof, and an immune detection method. The hybridoma cell line is prepared by fusing parental cells and myeloma cells, and has the characteristics represented by the cell line with the preservation number of PTA-11304. The parental cell line is prepared by the following steps that: prokaryotic cells are adopted to express non-structural protein coded by a 3ABC gene fragment of foot-and-mouth disease virus, the non-structural protein is adopted as antigen to immunize mice, and spleen cells of the immunized mice are taken out to prepare the parental cell line. The monoclonal antibody produced from the hybridoma cell line can provide specific recognition for the 3ABC peptide of the foot-and-mouth disease virus, and do not generate the non-specific reaction with the swine vesicular disease antiserum.

The present invention stems from the realization that the cell surface content of sialic acids is associated with drug susceptibility and resistance in neoplastic and damaged cells. A general decrease in the amounts of the α2-6 linked sialic acid has been confirmed in resistant phenotype compare to its corresponding sensitive parental cells. Treating the resistant phenotype with neuraminidase, an enzyme that removes the sialic acid from the sugar chain, facilitates the drug internalization and reinstalls the cell susceptibility to the drug. Based on these observations, methods for predicting the resistance to a number of drugs and detecting multi-drug resistanc in neoplastic and damaged cells have been invented.

New cell lines designated as Hepa-SC and Hepa-RP, originating from human hepatoma line HEPARG® are disclosed. Methods of inducing stemness in parental cells lines using mechano-transduction techniques, and redirecting stem-like cells to reprogrammed cells of a target differentiated population are also described.

The invention relates to a TOP medicament resistant cell line human ovarian cancer, with a accession number of CGMCC No 1217, which is selecting human ovarian cancer cell line as parental cell, putting the cell into RPMI1640 culture medium containing 15% calf serum, putting into incubator with 5% CO2 and 37 DEG C to culture; acquiring cells in logarithmic growth phase, counting after digesting with 0.25% pancreatin, inoculating 5*105/ml into culture bottle according to amount of 5ml in each bottle, when cells adheres to wall after 24 hours, reacting for 2 hours with a TOP final content of 2160ng/ml, discarding culture medium, washing by phosphate buffer for 3 times, replacing fresh culture medium, second impulsing after growing is resumed, and repeatedly operating, until it is impulsed with medicament for 13 times. The cell line is constructed for 10 months, medicament resistance of cell is 10.67 per cell, P<0.01 comparing with sensitive cell, has cross resistance to mitoxantrone, camptothecin, vincristine besides resistance to TOP.

The present invention relates to a method for increasing the efficiency of targeted integration of a polynucleotide to a pre-determined site into the genome of a filamentous fungal cell with a preference for NHR, wherein said polynucleotide has a region of homology with said pre-determined site, comprising steering an integration pathway towards HR. The present invention also relates to a mutant filamentous fungus originating from a parent cell, said mutant having an HR pathway with elevated efficiency and/or an NHR pathway with a lowered efficiency and/or a NHR/HR ratio with decreased efficiency as compared to said HR and/or NHR efficiency and/or NHR/HR ratio of said parent cell under the same conditions.

This invention provides improved cell lines for manufacture of protein-based pharmaceutical agents, considerably reducing the cost of commercial production. The cell lines are obtained by fusing cells from one or more parental cell populations. The hybrid cells are then selected for one or more characteristics that support protein production on a non-specific basis, such as the level of endoplasmic reticulum, Golgi apparatus, and/or other desired phenotypic features, compared with other hybrids or parental cells in the starting mixture. A gene encoding a therapeutic protein is transfected into the cells before or after one or more cycles of fusion and selection. Depending on the protein product being expressed, cell lines may be obtained that produce as much as eight grams or more of protein per liter of culture fluid.

The invention relates to a multidrug resistant cell strain for cervical carcinoma, which is characterized in that a human cervical carcinoma SiHa cell strain is selected as a parental cell; the action concentration of chemotherapeutics of cis-platinum (cDDP) is gradually increased from 0.1 mu g/ml to 0.2 mu g/ml; and drug resistant SiHa/ cDDP cell strain is established. The SiHa/cDDP cell can stably grow, transfer and reanimate in 2 mu g/ml cDDP, makes the cDDP generate drug resistant index (RI) of 16.131, and performs intersect drug on etoposide, taxol, vincristine, methotrexate, doxorubicin and mitomycin C except the cDDP. The invention aims to provide a drug resistant tumor cell model for relative study on the tumor.

The invention relates to two human choriocarcinoma multidrug resistant cell lines. The preservation numbers of the human choriocarcinoma multidrug resistant cell lines are CCTCC NO: C2018245 or CCTCCNO: C2018246. Human choriocarcinoma JAR and JEG3 cell lines are selected as parental cells, the action concentration of a chemotherapy drug methotrexate (MTX) is gradually increased from 11 micro moleper liter to 88 micro mole per liter to establish JAR/MTX (CCTCC NO: C2018245) and JEG3/MTX (CCTCC NO: C2018246) drug-resistant cell lines. The JAR/MTX and JEG3/MTX can stably grow, passage and recover in the MTX of 88 micro mole per liter, and have the drug resistance indexes of 791.50 and 1040.04 to the MTX, and not only have drug resistance to the MTX, but also have cross drug resistance to VP-16, 5-FU, Taxol and ACTD. After the drug resistant cell lines are established, drug withdrawal culture is performed for 3 months, liquid nitrogen freeze saving is performed for half a year, the cellsrecover, and the drug resistance of the cells is redetected, the drug resistance of the two drug resistant cell lines separately accounts for 90% or above of the original drug resistance, and the stability of the drug resistance of the drug resistant cell lines is very good.

The invention relates to a hybridoma which can generate a monoclonal antibody against human bladder cancer, and parental cells of which are B lymphocytes of a mouse and myeloma cells of the mouse immunized by E-J cells of a human bladder cancer cell line. The invention also relates to purposes and a preparation method of the hybridoma, the monoclonal antibody generated by the hybridoma, a directional drug against bladder cancer and a bladder cancer immunological diagnostic reagent and a preparation method of the directional drug. The antibody part of the directional drug serves as the monoclonal antibody against human bladder cancer. The diagnostic reagent is composed of an E-J cell lysis liquid of the human bladder cancer cell line and the monoclonal antibody DTB against human bladder cancer coated on an enzyme label plate, and the bladder cancer antigen in urine exfoliated cells is examined through adopting the competitive ELISA method. The specificity of the antibody of the hybridoma is strong; the tumor killing function of the directional drug of the hybridoma is strong without drug tolerance but good specificity; and the diagnostic reagent of the hybridoma has the advantages of damage resistance, high sensibility and specificity as well as convenience and quickness.

The invention belongs to the technical field of construction of tumor cell lines, and particularly relates to a tumor malignant clone cell line having important abnormal development disintegrating stage of mantle cell lymphoma, and a construction method and application of the tumor malignant clone cell line. The invention provides a human mantle cell lymphoma malignant clone cell strain containingearly malignant clone cells, is named as a human mantle cell lymphoma malignant clone cell strain JeKo-1-spheroid, and is preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is C2018264. A mature JeKo-1-parental cell strain is used as an induction object, a continuous culture and natural purification methods are used, a malignant clone cell strain containinga mantle cell lymphoma main malignant disintegrating stage is obtained, and the obtained cell strain highly cooperates with primary cells of a patient.

The invention relates to a multidrug resistant cell strain for cervical carcinoma, which is characterized in that a human cervical carcinoma SiHa cell strain is selected as a parental cell; the action concentration of chemotherapeutics of etoposide (VP16) is gradually increased from 0.1 mu g/ml to 4 mu g/ml; and drug resistant SiHa/VP16 cell strain is established. The SiHa/VP16 cell can stably grow, transfer and reanimate in 4 mu g/ml VP16, makes the VP16 generate drug resistant index (RI) of 24. 019, and performs intersect drug on MTX, cDDP, VCR, 5-Fu and DOX except VP16. The invention aims to provide a drug resistant tumor cell model for relative study on the tumor.

The invention discloses for the first time pluripotent cells, including hypoimmune pluripotent ABO blood type O Rhesus Factor negative (HIPO−) cells, that evade rejection by the host allogeneic immune system and avoid blood antigen type rejection. The HIPO− cells comprise reduced HLA-I and HLA-II expression, increased CD47 expression, and a universal blood group O Rh−(“O−”) blood type. The universal blood type is achieved by eliminating ABO blood group A and B antigents as well as eliminating Rh factor expression, or by starting with an O− parent cell line. These new, novel HIPO− cells evade host immune rejection because they have an impaired antigen presentation capacity, protection from innate immune clearance, and lack blood group rejection. The cells of the invention also include O− pluripotent stem cells (iPSCO−) and O− embryonic stem cells (ESCO−). The invention further provides universally acceptable “off”-the-shelf pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.

The present invention relates to methods of in vitro preparation of a parental cell bank (PCB) from foetal tissue consisting of foetal epiphyseal tissue, foetal Achilles tendon tissue and foetal skin tissue, using a rapid mechanical primary cell culture selection of cell type to be used in methods for wound and tissue repair.

The invention discloses an application of a breast cancer multidrug resistant protein molecule IBP, wherein the IBP has an amino acid sequence as shown in SEQ ID NO.11; studies find out that expression of the IBP in breast cancer multidrug resistant cells MCF-7/ADR is significantly higher than expression in MCF-7 parental cells, and moreover, after the expression of the IBP in the breast cancer cells is decreased, the sensibility on a variety of chemotherapy drugs is significantly enhanced; after the expression of the IBP in the MCF-7/ADR is interfered, the breast cancer drug-resistant cells can be inhibited, besides, expression and drug transport functions of MDR1 and other multidrug resistant related genes in the MCF-7/ADR are inhibited, and the drug sensitivity is increased; therefore, the IBP can be used as a multidrug resistant target gene for detection of breast cancer, and also can be used for preparing breast cancer multidrug resistant preparations or drugs.